Loading...
•
Sep 30, 2024
Gossamer Bio Q3 2024 Earnings Report
Gossamer Bio's financial performance and business progress were detailed for Q3 2024.
Key Takeaways
Gossamer Bio reported $327 million in cash, cash equivalents and marketable securities as of September 30, 2024. Revenue from contracts with collaborators was $9.5 million. R&D expenses were $34.9 million, and G&A expenses were $8.5 million. The net loss for the quarter was $30.8 million, or $0.14 per share.
Cash, cash equivalents, and marketable securities totaled $327.0 million as of September 30, 2024.
Revenue from contracts with collaborators was $9.5 million for the quarter ended September 30, 2024.
R&D expenses were $34.9 million for the quarter ended September 30, 2024.
Net loss for the quarter ended September 30, 2024, was $30.8 million, or $0.14 basic net loss per share.
Forward Guidance
Gossamer Bio anticipates a pivotal year in 2025 with Phase 3 PROSERA Study results in PAH and the commencement of a Phase 3 study in PH-ILD.
Positive Outlook
- Expect 2025 to be an exceptionally important year.
- Anticipate Phase 3 PROSERA Study results in PAH.
- Commence PH-ILD Phase 3 study.
- Completing PROSERA Study enrollment.
- Designing the registrational Phase 3 PH-ILD clinical trial.
Challenges Ahead
- Potential delays in the commencement, enrollment and completion of clinical trials
- Disruption to operations from the COVID-19 pandemic, including clinical trial delays
- Dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing
- Unexpected adverse side effects or inadequate efficacy of seralutinib that may limit their development, regulatory approval and/or commercialization, or may result in clinical holds, recalls or product liability claims
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...